Epifarma - Company finances
|
EUR
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|
|
Financial data
|
||
| Sales revenue | 70,615 | 198,882 |
| Profit before tax | 41,882 | 66,957 |
| Net profit | 39,768 | 62,923 |
| Equity | 42,268 | 67,191 |
| Liabilities | 3,817 | 11,687 |
| Non-current assets | 0 | 0 |
| Current assets | 46,085 | 78,878 |
| Total assets | 46,085 | 78,878 |
|
Taxes paid
|
||
| STI taxes | 8,718 | 44,013 |
|
Financial indicators
|
||
| Revenue change y/y | - | +181.6% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | 86.3% | 79.8% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | 94.1% | 93.6% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | 56.3% | 31.6% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | 59.3% | 33.7% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | 0.1 | 0.2 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | 70,615 | 198,882 |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
Epifarma - Social security debts
The company had no debts to Sodra
Epifarma - VMI tax arrears
| From | To | Overdue, € |
|---|---|---|
| 2026-01-08 | 2026-01-08 | 83.56 |
| 2026-01-05 | 2026-01-07 | 93.78 |
| 2026-01-01 | 2026-01-04 | 3.69 |
| 2025-12-05 | 2025-12-25 | 3.81 |
| 2025-12-02 | 2025-12-04 | 3.69 |
| 2025-11-28 | 2025-12-01 | 3.72 |
| 2025-11-27 | 2025-11-27 | 0.03 |
| 2025-11-07 | 2025-11-26 | 3.72 |
| 2025-11-06 | 2025-11-06 | 3.69 |
| 2025-11-02 | 2025-11-05 | 3.72 |
| 2025-10-30 | 2025-11-01 | 3.69 |
| 2025-09-28 | 2025-10-24 | 3.69 |
| 2025-09-06 | 2025-09-23 | 3.69 |
| 2025-08-28 | 2025-09-05 | 3.62 |
| 2025-08-02 | 2025-08-19 | 3.62 |
| 2025-07-31 | 2025-08-01 | 3.79 |
| 2025-07-28 | 2025-07-30 | 3.62 |
| 2025-06-28 | 2025-07-20 | 3.62 |
| 2025-06-19 | 2025-06-25 | 3.62 |
| 2025-06-04 | 2025-06-07 | 3.62 |
| 2025-06-02 | 2025-06-03 | 3.8 |
| 2025-05-31 | 2025-06-01 | 3.76 |
| 2025-05-29 | 2025-05-30 | 3.75 |
| 2025-05-07 | 2025-05-24 | 3.75 |
| 2025-05-03 | 2025-05-06 | 3.47 |
| 2025-05-01 | 2025-05-02 | 3.75 |
| 2025-04-30 | 2025-04-30 | 3.73 |
| 2025-04-28 | 2025-04-29 | 3.6 |
| 2025-04-05 | 2025-04-23 | 3.6 |
| 2025-04-04 | 2025-04-04 | 145.6 |
| 2025-03-28 | 2025-04-03 | 3.6 |
| 2025-03-20 | 2025-03-24 | 3.6 |
| 2025-02-28 | 2025-03-19 | 3.36 |
| 2024-12-31 | 2025-01-01 | 4.38 |
| 2024-12-30 | 2024-12-30 | 5392.0 |
| 2024-10-10 | 2024-10-16 | 0.53 |
| 2024-10-04 | 2024-10-09 | 42.0 |
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
Epifarma, UAB (code 306619119) is a Private Limited Liability Company engaged in the wholesale of other food. In the latest financial year, 2025, the company generated revenue of €198.9K, compared with €70.6K in 2024, showing strong year-on-year growth of 181.6%. Net profit increased from €39.8K in 2024 to €62.9K in 2025, while the profit margin was 31.6% in 2025, lower than the 56.3% recorded a year earlier but still indicating solid profitability. The balance sheet also expanded: total assets rose to €78.9K from €46.1K, equity increased to €67.2K, and liabilities grew to €11.7K. The company’s equity ratio stood at 85.2%, with debt-to-equity at 0.17, reflecting a low leverage position. Return on equity was 93.7% and return on assets 79.8%, supported by an asset turnover of 2.52x. Revenue per employee was €198.9K and profit per employee €62.9K in 2025, pointing to strong operational productivity.